pravastatin and avapro
pravastatin has been researched along with avapro in 9 studies
Research
Studies (9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Huang, Z; Jansson, L; Sjöholm, A | 3 |
| Adams, V; Erbs, S; Goettsch, W; Hambrecht, R; Holtz, J; Krekler, M; Kuss, O; Lenk, K; Mohr, FW; Morawietz, H; Schubert, A; Schuler, G | 1 |
| Divchev, D; Drexler, H; Grothusen, C; Koch, R; Luchtefeld, M; Onono, F; Schieffer, B; Thoenes, M | 1 |
Reviews
1 review(s) available for pravastatin and avapro
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Trials
2 trial(s) available for pravastatin and avapro
| Article | Year |
|---|---|
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Pressure; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Elective Surgical Procedures; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Irbesartan; Mammary Arteries; Membrane Glycoproteins; Muscle, Smooth, Vascular; NADPH Oxidase 2; NADPH Oxidases; Natriuretic Peptide, C-Type; Nitric Oxide Synthase Type III; Oxidative Stress; Polymerase Chain Reaction; Pravastatin; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Scavenger Receptors, Class E; Tetrazoles | 2006 |
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; C-Reactive Protein; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Group II Phospholipases A2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Tetrazoles; Treatment Outcome | 2008 |
Other Studies
6 other study(ies) available for pravastatin and avapro
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate.
Topics: Adrenal Glands; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; Captopril; Insulin; Irbesartan; Islets of Langerhans; Kidney; Male; Palmitic Acid; Pancreas; Pravastatin; Rats; Rats, Wistar; Regional Blood Flow; Tetrazoles | 2006 |
Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose; Captopril; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Irbesartan; Islets of Langerhans; Pancreas; Pravastatin; Rats; Rats, Wistar; Regional Blood Flow; Sex Factors; Tetrazoles; Vasodilator Agents | 2007 |
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Captopril; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Irbesartan; Islets of Langerhans; Male; Pravastatin; Rats; Rats, Mutant Strains; Regional Blood Flow; Sex Factors; Tetrazoles | 2008 |